
ABOUT EVONIK
Evonik serves as a global development partner and solutions provider to biotechnology companies to help them transform complexity into value. We bring together a broad, versatile range of core competencies, a trusted global network of sites, and strong technical expertise, to support you in the development, scale-up and manufacturing of biopharmaceutical products.
Areas of market leadership include high-purity amino acids, cell culture ingredients, lipid nanoparticle and polymeric-based drug products, tissue engineering, functional excipients, and biomaterials such as recombinant collagen. We are also one of the world's leading CDMOs for protein fermentation, APIs, advanced intermediates and biomaterials, with extensive formulation and process development support for large or complex projects.
Microbial fermentation
Evonik is one of the world’s leading custom contract manufacturing organizations for the production of high-quality substances including advanced food ingredients, cosmetics, nature-identical materials and APIs that leverage microbial fermentation.
- A comprehensive array of services from strain development through to large-scale commercial production
- Experience that spans more than 30 years
- Helped to bring to market more than 25 commercial products based on fermentation and biocatalytic technologies
- More than 4,000m³ of fermentation capacity across multiple high-quality sites, including flexible downstream processing
- Enzymatic chemistry expertise with >20 different enzymes applied at production scale
- A strong record in the development of new enzyme platforms (bacteria, algae, fungi)
Amino acids and derivatives
Evonik is one of the world’s leading and most trusted suppliers of pharmaceutical amino acids. For more than 40 years, customers have been leveraging our broad portfolio of highly pure natural and non-natural pharmaceutical amino acids, salts and derivatives. Our strong backward integration for starting materials manufactured at our large-scale fermentation facilities, can help to strengthen supply security and streamline your complete supply chain.
Evonik is far more than just a preferred global supplier of high purity amino acids, derivatives and peptides. We also serve as a development partner and solutions provider to many of the world’s pharmaceutical, biotech and nutraceutical customers. Our broad mix of core competencies across chemistry, biotechnology, drug delivery and cell culture uniquely position us to create long-term value. Customized amino acid solutions or regulatory services are provided in a range of areas including particle design, purification, packaging and analytical testing.
cQrex® cell culture solutions with industry recognized benefits
cQrex® is Evonik’s market-leading brand of cGMP-grade cell culture ingredients that are used by pharmaceutical and biotech companies to boost cell culture performance. Commercially proven for reliable media performance across countless biological programs, our cQrex® portfolio features a range of peptides and keto acids that we designed to address key issues in mammalian cell culture. The foundation stone for such outcomes are high-quality and animal origin-free amino acids, which have earned the industry’s finest reputation for batch-to-batch reproducibility at any clinical or commercial scale. All cell culture ingredients can be customized on-demand to address specific formulation requirements. In addition to screenings and booster development services, cQrex® customers can also benefit from our strong local knowledge of cell culture markets worldwide.
The cQrex® portfolio of dipeptides has been developed to provide customer solutions to the most challenging problems encountered with certain amino acids in high-performing cell culture processes. Based on their superior solubility, chemical stability and metabolic bioavailability, they have become essential tools in media development.
Contact us now to order your sample kit.
CONTACT INFORMATION
Evonik Corporation
2 Turner Place
Piscataway, NJ 08854
UNITED STATES
Phone: (732) 981-5021
Contact: Francine Clark
FEATURED ARTICLES
-
Efficient drug production through cell culture depends on the complex interplay between the drug molecule, the cell, and the process. How can you balance cell growth and productivity?
-
The market for biological drugs continues to grow at an impressive pace over the past years. Explore three key trends that will underpin the sustainable growth of biopharma beyond COVID-19.
-
Evonik Health Care's Dr. Martin Schilling and Johns Hopkins University Professor Michael Betenbaugh discuss advances and trends in cell culture-based production of biological drugs.
-
Discover how mRNA technologies open the doors to a whole range of new gene therapies and the role of lipid nanoparticles (LNPs) in current and future developments.
-
Evonik is one of the world's top 3 CMOs for API and intermediates. The brochure offers insight into their capabilities and the technologies they use to address the specific needs of the largest and most complex synthesis problems life science companies face today.
-
Key differences exist between liposomes and lipid nanoparticles (LNPs), not only in their target applications, but with their actual morphology, composition, and manufacturing process.
-
Cell therapies based on MSCs and T-cells have enabled a series of breakthroughs in patient care. Cell-based, engineered tissues are making significant contributions in the field of regenerative medicine.
-
The pandemic has highlighted vulnerabilities in the global supply chain. To reduce risk, initial steps are being taken to review how to increase local production capacities and tighten potential supply chain gaps.
-
Devices such as introducer sheaths, delivery catheters, endoscopes, and neurovascular microcatheters aim to minimize trauma during insertion and removal, reduce tissue inflammation, enable maneuverability through tortuous blood vessels, and improve patient comfort. Surface properties should promote smooth movement between certain device components.
-
Polymeric formulations such as intra-ocular implants designed for the precise intravitreal delivery of drug products represent one of the most promising, yet challenging, areas of pharmaceutical focus.
-
With the right selection of dipeptides, keto acids, special amino acids or other derivatives at hand, biopharma companies can realize substantial process improvements.
-
What applications are being explored for lipid nanoparticle delivery technologies? Dr. Jay Natarajan, Director of R&D, competence center for LNP technology, answers questions here.
-
The engagement of a CDMO partner with a broad portfolio of cell and gene therapy delivery technologies, a strong formulation track record and manufacturing flexibility is the preferred pathway for success.
-
Depending on the cell line, clone, product and media formulation used for biopharmaceutical production, it can be helpful to evaluate additional glutamine dipeptides to maximize performance.
-
Isabel Wahl, Head of Evonik’s RESOMER development lab, discusses a new bioresorbable copolymer combining mechanical strength with rapid degradation for wound healing and pediatric devices.
-
Advances in synthetic biology and genetic engineering have fueled the potential of fermentation-based manufacturing. Here we examine key trends and challenges to the approach.
-
Amino acids used in biopharma processes must be animal-origin free, governed by strict change control policies and utilize precise processes to eliminate endotoxins and heavy metals.
-
Few suppliers of standard or custom PEGs and mPEGs have the necessary competencies to address quality and purity requirements or to overcome technical manufacturing challenges.
-
While the solubility of free L-Cysteine is high at neutral pH, the applicable concentration in basal and feed media is limited. Read more about an available solution for solubility and performance challenges.
-
For pharma and biotech companies focused on the development of microbiome products, it's important to develop oral dosage forms that can deliver specific formulation or application outcomes.
-
The production of recombinant collagen made via fermentation-based processes addresses market needs for collagen that is safe, sustainable, reproducible, and acceptable to consumers.
-
Because L-Tyrosine is an important amino acid for protein synthesis and cellular metabolism, finding a solution to its solubility challenge can be critical to maximize process performance.
-
To meet growing market demand for the use of protein-based products that have a sustainable ecological footprint, substantial efforts are now underway to utilize microbial fermentation-based processes.
-
Cell culture media used in biopharma production have come a long way in recent decades. This interview discusses key solubility, stability and other challenges that many biopharma companies still face.
-
After more than 25 years of commercial use with almost 20 parenteral drug products, lipid nanoparticles (LNPs) are having a breakout moment. While LNPs are now a proven drug delivery technology to penetrate target cells and ensure release for reliable systematic or local delivery, their true market potential as a gene and cell therapy enabler has only become clear to many since COVID-19.
-
Traditional filling lines lack the necessary versatility to address the growing number of complex and personalized parenteral drug products that are now being brought to market. Evonik has recently qualified a new modular aseptic filling platform that will efficiently fill drug products in powder, liquid, suspension or combination form.
-
Discover some of the key expectations of customers who are reviewing CMOs to support the development and upscaling of their next major project.